Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 215   

Articles published

SNY 53.49 +0.01 (0.02%)
price chart
Sanofi SA (ADR) And Regeneron's $2.2B Pursuit Of Immuno-Oncology Drugs Is Late ...
Regeneron Pharmaceuticals Inc. and Sanofi announced a $2.2 billion collaboration on Tuesday in which the drug companies will pursue cancer treatments that pit the body's own immune system against tumors.
Sanofi SA And Regeneron Pharmaceuticals Extend Partnership In Cancer Treatments  Bidness ETC
Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA ...  Smarter Analyst
Amgen, Inc. Or Sanofi SA (ADR) - Who Will Rule The Cholesterol Market?
Amgen, Inc. (NYSE:AMGN) and Sanofi SA ADR (NYSE:SNY) are all set to change the cholesterol drug market with their powerful new treatments that belong to a new class of drugs called PCSK9 protein inhibitors.
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another Turmoil ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...
Driven By Amgen, Inc. And Sanofi SA (ADR), US Drug Price War May Shift From ...
As per research presented at the annual meeting of the American College of Cardiology in March and conducted separately by Amgen, Inc. (NASDAQ:AMGN), and Sanofi SA (ADR) (NYSE:SNY) along with its development partner Regeneron Pharmaceuticals ...
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.
Sanofi SA-Regeneron Pharmaceuticals Cholesterol Drug Well Tolerated But FDA ...
Sanofi SA (ADR) (NYSE:SNY), which jointly developed cholesterol-lowering drug Praluent with Regeneron Pharmaceuticals Inc (NASDAQ:REGN), received a setback Friday when the US Food and Drug Administration (FDA) said that while the drug ...
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals  Benzinga
How Big of an Impact Could Praluent Have on Regeneron Pharmaceuticals Inc.?  Motley Fool
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA (ADR ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent´┐Ż (alirocumab) Injection met its primary endpoint.
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin  Bidness ETC